Kathleen Moore to Doxorubicin
This is a "connection" page, showing publications Kathleen Moore has written about Doxorubicin.
Connection Strength
0.129
-
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer. 2010 Dec 01; 116(23):5407-14.
Score: 0.087
-
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
Score: 0.042